WO2004024710A1 - Composes a base d'uree, actifs en tant qu'antagonistes du recepteur de la vanilloide et utilises pour traiter les douleurs - Google Patents

Composes a base d'uree, actifs en tant qu'antagonistes du recepteur de la vanilloide et utilises pour traiter les douleurs Download PDF

Info

Publication number
WO2004024710A1
WO2004024710A1 PCT/EP2003/010262 EP0310262W WO2004024710A1 WO 2004024710 A1 WO2004024710 A1 WO 2004024710A1 EP 0310262 W EP0310262 W EP 0310262W WO 2004024710 A1 WO2004024710 A1 WO 2004024710A1
Authority
WO
WIPO (PCT)
Prior art keywords
formula
compound
alkyl
nr4r5
quinolinyl
Prior art date
Application number
PCT/EP2003/010262
Other languages
English (en)
Inventor
Gregor James Macdonald
Stephen Frederick Moss
Harshad Kantilal Rami
Mervyn Thompson
David Richard Witty
Original Assignee
Glaxo Group Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0221317A external-priority patent/GB0221317D0/en
Priority claimed from GB0305293A external-priority patent/GB0305293D0/en
Application filed by Glaxo Group Limited filed Critical Glaxo Group Limited
Priority to AU2003270199A priority Critical patent/AU2003270199A1/en
Publication of WO2004024710A1 publication Critical patent/WO2004024710A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Definitions

  • This invention relates to novel compounds, especially urea derivatives, having pharmacological activity, processes for their preparation, to compositions containing them and to their use in medicine, especially in the treatment of various disorders.
  • Vanilloids are a class of natural and synthetic compounds that are characterised by the presence of a vanillyl (4-hydroxy 3-methoxybenzyl) group or a functionally equivalent group. Vanilloid Receptor (VR-1), whose function is modulated by such compounds, has been widely studied and is extensively reviewed by Szallasi and Blumberg (The American Society for Pharmacology and Experimental Therapeutics, 1999, Vol. 51 , No. 2.).
  • Vanilloid compounds of different structures are known in the art, for example those disclosed in European Patent Application Numbers, EP 0 347 000 and EP 0 401 903, UK Patent Application Number GB 2226313 and International Patent Application, Publication Numbers WO 92/09285, WO 02/100819, WO 02/076946, WO 02/090326 and WO 02/072536.
  • vanilloid compounds or vanilloid receptor modulators are capsaicin or trans 8-methyl-N-vanillyl-6-nonenamide which is isolated from the pepper plant, capsazepine (Tetrahedron, 53, 1997, 4791) and olvanil or - N-(4- hydroxy-3-methoxybenzyl)oleamide (J. Med. Chem., 36, 1993, 2595).
  • US Patent Numbers, US 3,424,760 and US 3,424,761 both describe a series of 3-Ureidopyrrolidines that are said to exhibit analgesic, central nervous system, and pyschopharmacological activities. These patents specifically disclose the compounds 1-(1-phenyl-3-pyrrolidinyl)-3-phenyl urea and 1-(1- phenyl-3-pyrrolidinyl)-3-(4-methoxyphenyl)urea respectively.
  • P is selected from benzisothiazolyl, cinnolinyl, phenyl, phthalazinyl, quinazolinyl, quinolinyl or iso-quinolinyl
  • P' is selected from cinnolinyl, phenyl, pyridazinyl, pyridinyl, pyrimidinyl, thiazolyl, quinolinyl or iso-quinolinyl;
  • Ri and R2 are independently selected from -H, halo, alkyl, alkoxy, cycloalkyl, aralkyl, aralkoxy, cycloalkylalkyl, cycloalkylalkoxy, -CN, -NO2, -OH, -OCF3, -CF3, -NR R5 -S(O) m R 6 , -S(O) 2 NR4R5, -OS(O) 2 R 6 , -OS(0) 2 CF 3 , -O(CH 2 ) x NR 4 R 5 , -C(O)CF 3 , -C(O)alkyl, -C(O)cycloalkyl, -C(O)aralkyl, -C(O)Ar, -C(O)(CH 2 ) x OR6, - C(O)(CH 2 ) X NR4R5, -C(O)alkoxy, -C(O)NR 4
  • R4 and R ⁇ may be the same or different and represent H or alkyl; or R4 and R 5 together with the nitrogen atom to which they are attached form a heterocyclic ring;
  • Z is a bond, O, S or NR?;
  • R 6 is alkyl or aryl;
  • R 7 is hydrogen, alkyl or aryl
  • Ar is phenyl, which may be optionally substituted by one or more halo atoms; m is 1 or 2; n is 0, 1 , 2 or 3; p and q are independently 0, 1 , 2, 3 or 4; r is 1 , 2 or 3; s is 0, 1 or 2; and x is 0, 1 , 2, 3, 4, 5 or 6; with the proviso that when P is phenyl, quinolinyl or iso-quinolinyl then P' is cinnolinyl, pyridazinyl, pyrimidinyl, thiazolyl, quinolinyl or iso-quinolinyl.
  • P is phenyl, 7-benzisothiazolyl, 5-cinnolinyl, 5-phthalazinyl, 8- quinazolinyl, 5-quinolinyl, 7-quinolinyl, 5-isoquinolinyl or 8-isoquinolinyl.
  • P is phenyl. More preferably, P is cinnolinyl or benzisothiazolyl. Most preferably, P is cinnolinyl.
  • P' is phenyl, 2-pyridinyl, 2-pyrimidinyl, 3-pyridazinyl, 2-thiazolyl, 5-cinnolinyl, 5-quinolinyl or 5-isoquinolinyl.
  • P' is pyridinyl or iso- quinolinyl.
  • P' is pyridinyl.
  • R 1 is halo, alkyl, alkoxy, -CN, -CF3 or -OCF3.
  • R 1 is fluoro, chloro, bromo, methyl, ferf-butyl, so-propoxy, -CN, -CF3 or -OCF3.
  • p is 1 or 2.
  • n is 0 or 1.
  • n is 0.
  • R 2 is halo, alkyl, alkoxy, -CN or CF3.
  • R 2 is chloro, bromo, methyl, methoxy, -CN or -CF3.
  • the groups R2 may be the same or different.
  • q is 1 or 2.
  • r and s have values such that they define a 4 - 7 membered ring.
  • r and s have values such that they define a 5 or 6 membered ring, most preferably a 5 membered ring.
  • x is 1 , 2 or 3. According to a further aspect of the present invention, there is provided a subset of compounds of formula (I), of formula (IA),
  • p1 is selected from benzisothiazolyl, cinnolinyl, phthalazinyl or quinazolinyl
  • p2 is selected from cinnolinyl, pyridazinyl, pyrimidinyl, thiazolyl, quinolinyl or iso- quinolinyl
  • R1 and R2 are independently selected from -H, halo, alkyl, alkoxy, cycloalkyl, aralkyl, aralkoxy, cycloalkylalkyl, cycloalkylalkoxy, -CN, -NO 2 , -OH, -OCF3, -CF3, -NR4R5, -S(0) m R6, -S(O) 2 NR4R5, -OS(O) 2 R 6 , -OS(O) 2 CF 3 , -O(CH 2 ) X NR R5, -C(O)CF 3 , -C(O)alkyl, -C(O)cycloalkyl, -C(O)aralkyl, -C(O)Ar, -C(O)(CH 2 ) X OR6, - C(O)(CH 2 ) X NR4R5, -C(O)alkoxy, -C(O)NR R5,
  • R4 and R 5 may be the same or different and represent H or alkyl; or R4 and R 5 together with the nitrogen atom to which they are attached form a heterocyclic ring;
  • Z is a bond, O, S or NR 7 ;
  • R 6 is alkyl or aryl;
  • R 7 is hydrogen, alkyl or aryl;
  • Ar is phenyl, which may be optionally substituted by one or more halo atoms; m is 1 or 2; n is 0, 1 , 2 or 3; p and q are independently 0, 1 , 2, 3 or 4; r is 1 , 2 or 3; s is 0, 1 or 2; and x is O, 1 , 2, 3, 4, 5 or 6.
  • p1 is cinnolinyl or benzisothiazolyl.
  • p1 is cinnolinyl.
  • p2 is pyridazinyl, pyrimidinyl or iso-quinolinyl.
  • p2 is iso-quinolinyl.
  • R 1 is halo, alkyl, alkoxy, -CN, -CF3 or -OCF3.
  • R is alkyl.
  • R ⁇ is methyl.
  • the groups R ⁇ may be the same or different.
  • p is 1 or 2.
  • n is 0 or 1.
  • n is 0.
  • R 2 is halo, alkyl, alkoxy, -CN or -CF3.
  • R2 is methyl or -CF 3 .
  • q is 2 or 3 the groups R may be the same or different.
  • q is 1 or 2.
  • r and s have values such that they define a 4 - 7 membered ring.
  • r and s have values such that they define a 5 or 6 membered ring, most preferably a 5 membered ring.
  • x is 1 , 2 or 3.
  • Certain of the carbon atoms of formula (I) are chiral carbon atoms, such as the carbon atom marked with an "*", and therefore compounds of formula (I) may exist as stereoisomers.
  • the invention extends to all optical isomers such as stereoisomeric forms of the compounds of formula (I) including enantiomers and mixtures thereof, such as racemates.
  • the different stereoisomeric forms may be separated or resolved one from the other by conventional methods or any given isomer may be obtained by conventional stereospecific or asymmetric syntheses.
  • Preferred compounds of formula (I) have the C* carbon in the R- configuration. Certain of the compounds herein can exist in various tautomeric forms and it is to be understood that the invention encompasses all such tautomeric forms.
  • the compounds of formula (I) can form salts, especially pharmaceutically acceptable salts.
  • Suitable pharmaceutically acceptable salts are those use conventionally in the art and include those described in J. Pharm. Sci., 1977, 66, 1-19, such as acid addition salts.
  • Suitable pharmaceutically acceptable salts include acid addition salts.
  • Suitable pharmaceutically acceptable acid addition salts include salts with inorganic acids such, for example, as hydrochloric acid, hydrobromic acid, orthophosphoric acid or sulphuric acid, or with organic acids such, for example as methanesulphonic acid, toluenesulphonic acid, acetic acid, propionic acid, lactic acid, citric acid, fumaric acid, malic acid, succinic acid, salicylic acid, maleic acid, glycerophosphoric acid or acetylsalicylic acid.
  • the salts and/or solvates of the compounds of the formula (I) which are not pharmaceutically acceptable may be useful as intermediates in the preparation of pharmaceutically acceptable salts and/or solvates of compounds of formula (I) or the compounds of the formula (I) themselves, and as such form another aspect of the present invention.
  • the compounds of formula (I) may be prepared in crystalline or non-crystalline form, and if crystalline, may be optionally hydrated or solvated. This invention includes in its scope stoichiometric hydrates as well as compounds containing variable amounts of water.
  • Suitable solvates include pharmaceutically acceptable solvates, such as hydrates.
  • Solvates include stoichiometric solvates and non-stoichiometric solvates.
  • alkyl as a group or part of a group refers to a straight or branched chain saturated aliphatic hydrocarbon radical containing 1 to 12 carbon atoms, suitably 1 to 6 carbon atoms.
  • alkyl groups in particular include methyl (“Me”), ethyl ("Et”), n-propyl (“Pr 11 "), /so-propyl (“Pr””), n-butyl
  • alkyl groups may be substituted by one or more groups selected from halo (such as fluoro, chloro, bromo), -CN, -CF3, -OH, -OCF3, C 2 _ ⁇ alkenyl, C _Q alkynyl, C-j. ⁇ alkoxy, aryl and di-C-j.g alkylamino.
  • alkoxy refers to an alkyl ether radical, wherein the term “alkyl” is defined above.
  • alkoxy groups in particular include methoxy, ethoxy, n-propoxy, / ' so-propoxy, n-butoxy, /so-butoxy, sec-butoxy and te/ ⁇ -butoxy.
  • alkoxy groups may be substituted by one or more groups selected from halo (such as fluoro, chloro, bromo), -CN, -CF3, -OH, -OCF3, C-J.Q alkyl, C 2 _ ⁇ alkenyl, C ⁇ .Q alkynyl, aryl and di-C-j.g alkylamino.
  • aryl as a group or part of a group refers to a carbocyclic aromatic radical ("Ar").
  • aryl groups are 5-6 membered monocyclic groups or 8-10 membered fused bicyclic groups, especially phenyl ("Ph”), biphenyl and naphthyl, particularly phenyl.
  • halo is used herein to describe, unless otherwise stated, a group selected from fluorine ("fluoro"), chlorine (“chloro”), bromine (“bromo”) or iodine ("iodo").
  • naphthyl is used herein to denote, unless otherwise stated, both naphth-1-yl and naphth-2-yl groups.
  • the present invention also provides a process for the preparation of a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof, which process comprises coupling a compound of formula (II):
  • P ⁇ R2, n, q, r and s are as defined in formula (I) and A and B contain appropriate functional groups which are capable of reacting together to form the urea moiety; and thereafter, as necessary, carrying out one or more of the following reactions: (i) converting one compound of formula (I) into another compound of formula (I); (ii) removing any protecting group; (iii) preparing a salt or a solvate of the compound so formed.
  • Suitable examples of appropriate A and B groups include:
  • A is NH 2 and B is NH 2 together with an appropriate urea forming agent.
  • the reaction is carried out in an inert solvent such as dichloromethane or acetonitrile.
  • the urea forming agent can be carbonyl diimidazole or phosgene ortriphosgene, and carried out in an inert organic solvent such as diethyl ether, tetrahydrofuran or dichloromethane at ambient or elevated temperature in the presence of a base such as triethylamine or pyridine.
  • An alternative method of synthesis of the unsymmetrical urea compounds of formula (I) is from a diaryl carbonate, via the corresponding carbamate. Such a methodology is described by Freer et al. (Synthetic Communications, 26(2), 331 - 349, 1996). It would be appreciated by those skilled in the art that such a methodology could be readily adapted for preparation of the compounds of formula (I).
  • a further method of synthesis is using phenyl chloroformate as described by B.R.Baker et al., J.Med.Chem., 1969, 12, 672-6. It will be appreciated by those skilled in the art that it may be necessary to protect certain reactive substituents during some of the above-mentioned procedures. Standard protection and deprotection techniques, such as those described in Greene T.W. 'Protective groups in organic synthesis', New York, Wiley (1981), can be used. For example, primary amines can be protected as phthalimide, benzyl, benzyloxycarbonyl or trityl derivatives. Carboxylic acid groups can be protected as esters.
  • a compound of formula (III) may be prepared by reaction of a compound of formula (IV):
  • B' is B as defined above or a protected form thereof and n, r and s are as defined above.
  • lJ is a halogen, such as chlorine.
  • the compound of formula (V) is in an activated form, for example an ionic form.
  • activated forms are prepared using conventional coupling reaction methodology, as for example by reacting compounds (IV) and (V) in the presence of an alkali carbonate, such as potassium carbonate, in an aprotic solvent such as dimethylformamide using reaction conditions appropriate to the particular methodology chosen, for example at an elevated temperature, such as 100°C.
  • compositions may be prepared conventionally by reaction with the appropriate acid or acid derivative.
  • Vanilloid receptor antagonist V1
  • V1 Vanilloid receptor antagonist
  • neuropathic pain neuropathic pain
  • postoperative pain postrheumatoid arthritic pain
  • osteoarthritic pain back pain
  • visceral pain cancer pain, algesia, neuralgia, dental pain, headache, migraine, neuropathies, carpal tunnel syndrome, diabetic neuropathy, HIV-related neuropathy, post-herpetic neuralgia, fibromyalgia, neuritis, sciatica, nerve injury, ischaemia, neurodegeneration, stroke, post stroke pain, multiple sclerosis, respiratory diseases, asthma, cough, COPD, broncho constriction, inflammatory disorders, oesophagitis, heart burn, Barrett's metaplasia, dysphagia, gastroeosophageal relux disorder (GERD), stomach
  • the compounds of the present invention are also indicated to be useful in the treatment and/or prophylaxis of pelvic pain, renal colic, biliary colic, functional dyspepsia, Barrett's metaplasia, dysphagia and pain associated therewith
  • the invention also provides a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof, for use as an active therapeutic substance, in particular, in the treatment and/or prophylaxis of the
  • the invention provides a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof for use in the treatment or prophylaxis of pain.
  • the invention further provides a method for the treatment or prophylaxis of disorders in which antagonism of the Vanilloid (VR1 ) receptor is beneficial, in particular the Primary Disorders of the Invention, in mammals including humans, which comprises administering to a mammal in need thereof a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof.
  • the invention further provides a method for the treatment or prophylaxis of disorders in which antagonism of the Vanilloid (VR1) receptor is beneficial, in particular the Secondary Disorders of the Invention, in mammals including humans, which comprises administering to a mammal in need thereof a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof.
  • a method for the treatment or prophylaxis of disorders in which antagonism of the Vanilloid (VR1) receptor is beneficial in particular the Secondary Disorders of the Invention, in mammals including humans, which comprises administering to a mammal in need thereof a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof.
  • the invention provides for the use of a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof in the manufacture of a medicament for the treatment or prophylaxis of disorders in which antagonism of the Vanilloid (VR1) receptor is beneficial, particularly the Primary and/or Secondary
  • the present invention also provides a pharmaceutical composition, which comprises a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof and a pharmaceutically acceptable carrier or excipient therefor.
  • a pharmaceutical composition of the invention which may be prepared by admixture, suitably at ambient temperature and atmospheric pressure, is usually adapted for oral, parenteral, rectal administration or intravesical administration to the bladder and, as such, may be in the form of tablets, capsules, oral liquid preparations, powders, granules, lozenges, reconstitutable powders, injectable or infusable solutions, suspensions or suppositories. Orally administrable compositions are generally preferred.
  • Tablets and capsules for oral administration may be in unit dose form, and may contain conventional excipients, such as binding agents, fillers, tabletting lubricants, disintegrants and acceptable wetting agents.
  • the tablets may be coated according to methods well known in normal pharmaceutical practice.
  • Oral liquid preparations may be in the form of, for example, aqueous or oily suspension, solutions, emulsions, syrups or elixirs, or may be in the form of a dry product for reconstitution with water or other suitable vehicle before use.
  • Such liquid preparations may contain conventional additives such as suspending agents, emulsifying agents, non-aqueous vehicles (which may include edible oils), preservatives, and, if desired, conventional flavourings or colourants.
  • fluid unit dosage forms are prepared utilising a compound of the invention or pharmaceutically acceptable salt thereof and a sterile vehicle.
  • the compound depending on the vehicle and concentration used, can be either suspended or dissolved in the vehicle.
  • the compound can be dissolved for injection and filter sterilised before filling into a suitable vial or ampoule and sealing.
  • adjuvants such as a local anaesthetic, preservatives and buffering agents are dissolved in the vehicle.
  • the composition can be frozen after filling into the vial and the water removed under vacuum.
  • Parenteral suspensions are prepared in substantially the same manner, except that the compound is suspended in the vehicle instead of being dissolved, and sterilization cannot be accomplished by filtration.
  • the compound can be sterilised by exposure to ethylene oxide before suspension in a sterile vehicle.
  • a surfactant or wetting agent is included in the composition to facilitate uniform distribution of the compound.
  • composition may contain from 0.1 % to 99% by weight, preferably from 10 to 60% by weight, of the active material, depending on the method of administration.
  • suitable unit doses may be 0.05 to 1000 mg, more suitably 0.05 to 20, 20 to 250, or 0.1 to 500.0 mg, for example 0.2 to 5 and 0.1 to 250 mg; and such unit doses may be administered more than once a day, for example two or three a day, so that the total daily dosage is in the range of about 0.5 to 1000 mg; and such therapy may extend for a number of weeks or months.
  • 5-Aminophthalazine was prepared according to the procedure outlined in the literature (J. Chem Soc, Perkin Trans. 1 , 1993, 2, 211-216).
  • 8-Aminoquinazoline was prepared according to the procedure outlined in the literature (J. Org. Chem., 1947, 12, 405-421 ).
  • the compounds of the invention are vanilloid receptor (VR1 ) antagonists and hence have useful pharmaceutical properties.
  • Vanilloid receptor (VR1) antagonist activity can be confirmed and demonstrated for any particular compound by use of conventional methods, for example those disclosed in standard reference texts such as D. Le Bars, M. Gozarin and S. W. Cadden, Pharmacological Reviews, 2001 , 53(4), 597-652] or such other texts mentioned herein.
  • the screen used for the compounds of this invention was based upon a FLIPR based calcium assay, similar to that described by Smart et al. (British Journal of Pharmacology, 2000, 129, 227-230).
  • Transfected astrocytoma 1321 N1 cells, stably expressing human VR1 were seeded into FLIPR plates at 25,000cells/well (96-well plate) and cultured overnight.
  • the cells were subsequently loaded in medium containing 4 ⁇ M Fluo-3 AM (Molecular Probes) for 2 hours, at room temperature, in the dark. The plates were then washed 4 times with Tyrode containing 1.5mM calcium, without probenecid. The cells were pre-incubated with compound or buffer control at room temperature for 30 minutes. Capsaicin (Sigma) was then added to the cells. Compounds having antagonist activity against the human VR1 were identified by detecting differences in fluorescence when measured after capsaicin addition, compared with no compound buffer controls. Thus, for example, in the buffer control capsaicin addition results in an increase in intracellular calcium concentration resulting in fluorescence.
  • Fluo-3 AM Molecular Probes
  • FCA 1mg/ml FCA was injected intraplantar into the left paw of 4 groups of 8 male Dunkin Hartley guinea-pigs (batch: 6282434, average weight 340g). 24 hours later compounds were administered orally at 0 (vehicle), 3, 10 30mg/kg with vehicle as 1%methylcellulose and dosing volume being 2ml/kg and dosing straight into the stomach. The methylcellulose was added gradually to the compound into the pestle and mortar and ground together.
  • Behavioural readouts of mechanical hyperalgesia were obtained before FCA administration (naive reading), after FCA but before drug administration (predose reading) and 1 hour after drug administration.
  • the readout used was paw pressure (Randall-Sellito) and the end point was paw withdrawal.
  • the paw pressure equipment also had one silver disc placed on the point to increase the markings by a factor of 2.

Abstract

Cette invention a trait à certains composés, correspondant à la formule (I), ou à un sel ou un solvate de ceux-ci, acceptables du point de vue pharmaceutique. Dans cette formule, R1, R2, P, P', n, p, q, r et s sont tels que définis dans le descriptif. L'invention concerne également un procédé de préparation de ces composés, une composition pharmaceutique contenant ces composés ainsi que l'usage qui est fait de ces composés en médecine.
PCT/EP2003/010262 2002-09-13 2003-09-11 Composes a base d'uree, actifs en tant qu'antagonistes du recepteur de la vanilloide et utilises pour traiter les douleurs WO2004024710A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003270199A AU2003270199A1 (en) 2002-09-13 2003-09-11 Urea compounds active as vanilloid receptor antagonists for the treatment of pain

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0221317A GB0221317D0 (en) 2002-09-13 2002-09-13 Novel compounds
GB0221317.1 2002-09-13
GB0305293A GB0305293D0 (en) 2003-03-07 2003-03-07 Novel compounds
GB0305293.3 2003-03-07

Publications (1)

Publication Number Publication Date
WO2004024710A1 true WO2004024710A1 (fr) 2004-03-25

Family

ID=31995703

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2003/010262 WO2004024710A1 (fr) 2002-09-13 2003-09-11 Composes a base d'uree, actifs en tant qu'antagonistes du recepteur de la vanilloide et utilises pour traiter les douleurs

Country Status (2)

Country Link
AU (1) AU2003270199A1 (fr)
WO (1) WO2004024710A1 (fr)

Cited By (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004078744A2 (fr) * 2003-03-07 2004-09-16 Glaxo Group Limited Derives d'uree
WO2004078749A1 (fr) * 2003-03-06 2004-09-16 Glaxo Group Limited Derives d'uree heterocycliques pour le traitement de la douleur
WO2004078101A2 (fr) * 2003-03-08 2004-09-16 Glaxo Group Limited Derives d'uree
WO2005016915A1 (fr) 2003-08-14 2005-02-24 Glaxo Group Limited Derives carboxamides de piperidine/cyclohexane destines a etre utilises comme modulateurs du recepteur vanilloide
JPWO2005095327A1 (ja) * 2004-03-31 2008-02-21 味の素株式会社 アニリン誘導体
JP2008506695A (ja) * 2004-07-13 2008-03-06 グラクソ　グループ　リミテッド 抗細菌剤
WO2008028690A1 (fr) * 2006-09-07 2008-03-13 Bayer Schering Pharma Aktiengesellschaft 1-(hét)aryle-3-[hétaryle-pipéridine-4-yle]-thiourées utilisées en tant que modulateurs du récepteur ep2
EP2036902A3 (fr) * 2001-09-13 2009-05-06 Glaxo Group Limited Derives de l'uree actifs comme antagonistes des recepteurs vanilloides
JP2009530287A (ja) * 2006-03-13 2009-08-27 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 高血圧、炎症および他の疾患の治療のための可溶性エポキシドヒドロラーゼの阻害剤としてのピペリジニル、インドリル、ピリニジル、モルホリニルおよびベンズイミダゾリル尿素誘導体
US7618993B2 (en) 2005-12-23 2009-11-17 Astrazeneca Ab Compounds
US7645784B2 (en) 2003-05-16 2010-01-12 Astrazeneca Ab Benzimidazole derivatives
US7728005B2 (en) 2003-10-14 2010-06-01 Ajinomoto Co., Inc. Ether derivative
JP2010530438A (ja) * 2007-06-21 2010-09-09 アイアールエム・リミテッド・ライアビリティ・カンパニー プロテインキナーゼ阻害剤およびその使用法
US7906654B2 (en) 2006-08-11 2011-03-15 Astrazeneca Ab Benzimidazole derivatives
US7994167B2 (en) 2005-05-20 2011-08-09 Gruenenthal Gmbh Pentafluorosulphanyl-substituted compound and its use for producing medicaments
US8557872B2 (en) 2008-01-28 2013-10-15 Amorepacific Corporation Compounds, isomer thereof, or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist; and pharmaceutical compositions containing the same
US8653262B2 (en) 2007-05-31 2014-02-18 Boehringer Ingelheim International Gmbh CCR2 receptor antagonists and uses thereof
US8691855B2 (en) 2008-07-02 2014-04-08 Amorepacific Corporation Compounds, isomer thereof, or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist and pharmaceutical compositions containing the same
US8765949B2 (en) 2009-12-17 2014-07-01 Boehringer Ingelheim International Gmbh CCR2 receptor antagonists and uses thereof
US8835440B2 (en) 2008-12-19 2014-09-16 Boehringer Ingelheim International Gmbh Cyclic pyrimidin-4-carboxamides as CCR2 receptor antagonists for treatment of inflammation, asthma and COPD
US8841313B2 (en) 2010-05-17 2014-09-23 Boehringer Ingelheim International Gmbh CCR2 antagonists and uses thereof
US8877745B2 (en) 2010-05-12 2014-11-04 Boehringer Ingelheim International Gmbh CCR2 receptor antagonists, method for producing the same, and use thereof as medicaments
US8946218B2 (en) 2010-05-12 2015-02-03 Boehringer Ingelheim International Gmbh CCR2 receptor antagonists, method for producing the same, and use thereof as medicaments
US8962656B2 (en) 2010-06-01 2015-02-24 Boehringer Ingelheim International Gmbh CCR2 antagonists
US9018212B2 (en) 2010-05-25 2015-04-28 Boehringer Ingelheim International Gmbh Pyridazine carboxamides as CCR2 receptor antagonists
US9108958B2 (en) 2011-07-15 2015-08-18 Boehringer Ingelheim International Gmbh Selective CCR2 antagonists
US10213428B2 (en) 2015-07-02 2019-02-26 Centrexion Therapeutics Corporation (4-((3R,4R)-3-methoxytetrahydro-pyran-4-ylamino)piperidin-1-yl)(5-methyl-6-(((2R,6S)-6-(p-tolyl)tetrahydro-2H-pyran-2-yl)methylamino)pyrimidin-4-yl)methanone citrate
DE102022104759A1 (de) 2022-02-28 2023-08-31 SCi Kontor GmbH Co-Kristall-Screening Verfahren, insbesondere zur Herstellung von Co-Kristallen

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3424761A (en) * 1966-03-07 1969-01-28 Robins Co Inc A H 3-ureidopyrrolidines
US4001422A (en) * 1974-07-25 1977-01-04 Pfizer Inc. 4-aminoquinazoline cardiac stimulants
WO2002022592A2 (fr) * 2000-09-14 2002-03-21 Schering Corporation Antagonistes du recepteur y.y5 de neuropeptide d'urease substitue
WO2002090326A1 (fr) * 2001-05-02 2002-11-14 Smithkline Beecham P.L.C. Urees heterocycliques, leur preparation et leur utilisation comme antagonistes du recepteur vanilloide
WO2003022809A2 (fr) * 2001-09-13 2003-03-20 Smithkline Beecham P.L.C. Nouveaux composes
WO2003076421A1 (fr) * 2002-03-13 2003-09-18 Janssen Pharmaceutica N.V. Derives aminocarbonyl utilises en tant que nouveaux inhibiteurs d'histone deacetylase

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3424761A (en) * 1966-03-07 1969-01-28 Robins Co Inc A H 3-ureidopyrrolidines
US4001422A (en) * 1974-07-25 1977-01-04 Pfizer Inc. 4-aminoquinazoline cardiac stimulants
WO2002022592A2 (fr) * 2000-09-14 2002-03-21 Schering Corporation Antagonistes du recepteur y.y5 de neuropeptide d'urease substitue
WO2002090326A1 (fr) * 2001-05-02 2002-11-14 Smithkline Beecham P.L.C. Urees heterocycliques, leur preparation et leur utilisation comme antagonistes du recepteur vanilloide
WO2003022809A2 (fr) * 2001-09-13 2003-03-20 Smithkline Beecham P.L.C. Nouveaux composes
WO2003076421A1 (fr) * 2002-03-13 2003-09-18 Janssen Pharmaceutica N.V. Derives aminocarbonyl utilises en tant que nouveaux inhibiteurs d'histone deacetylase

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
"Maybridge HTS", 5 September 2003, MAYBRIDGE PLC, TINTAGEL, CORNWALL, PL34 0HW, UK *
DATABASE CHEMCATS Chemical Abstract Service, Colombus, Ohio, US; XP002265888 *
MASTERS J J ET AL: "Non-Amidine-Containing 1,2-Dibenzamidobenzene Inhibitors of Human Factor Xa with Potent Anticoagulant and Antithrombotic Activity", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 43, 2000, pages 2087 - 2092, XP002238143, ISSN: 0022-2623 *

Cited By (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8063078B2 (en) 2001-09-13 2011-11-22 Glaxosmithkline Llc Urea-compounds active as vanilloid receptor antagonists for the treatment of pain
EP2036902A3 (fr) * 2001-09-13 2009-05-06 Glaxo Group Limited Derives de l'uree actifs comme antagonistes des recepteurs vanilloides
WO2004078749A1 (fr) * 2003-03-06 2004-09-16 Glaxo Group Limited Derives d'uree heterocycliques pour le traitement de la douleur
US7528151B2 (en) 2003-03-06 2009-05-05 Glaxo Group Limited Heterocyclic urea derivatives for the treatment of pain
WO2004078744A3 (fr) * 2003-03-07 2005-01-13 Glaxo Group Ltd Derives d'uree
WO2004078744A2 (fr) * 2003-03-07 2004-09-16 Glaxo Group Limited Derives d'uree
US7514562B2 (en) 2003-03-07 2009-04-07 Glaxo Group Limited Urea derivatives and their use as vanilloid receptor antagonists in the treatment of pain
US7528150B2 (en) 2003-03-08 2009-05-05 Glaxo Group Limited Urea derivatives having vanilloid receptor antagonist activity
WO2004078101A2 (fr) * 2003-03-08 2004-09-16 Glaxo Group Limited Derives d'uree
WO2004078101A3 (fr) * 2003-03-08 2005-02-17 Glaxo Group Ltd Derives d'uree
US7645784B2 (en) 2003-05-16 2010-01-12 Astrazeneca Ab Benzimidazole derivatives
WO2005016915A1 (fr) 2003-08-14 2005-02-24 Glaxo Group Limited Derives carboxamides de piperidine/cyclohexane destines a etre utilises comme modulateurs du recepteur vanilloide
US7728005B2 (en) 2003-10-14 2010-06-01 Ajinomoto Co., Inc. Ether derivative
US7879863B2 (en) 2004-03-31 2011-02-01 Ajinomoto Co., Inc. Aniline derivatives
JPWO2005095327A1 (ja) * 2004-03-31 2008-02-21 味の素株式会社 アニリン誘導体
JP4775259B2 (ja) * 2004-03-31 2011-09-21 味の素株式会社 アニリン誘導体
JP2008506695A (ja) * 2004-07-13 2008-03-06 グラクソ　グループ　リミテッド 抗細菌剤
US7994167B2 (en) 2005-05-20 2011-08-09 Gruenenthal Gmbh Pentafluorosulphanyl-substituted compound and its use for producing medicaments
US7618993B2 (en) 2005-12-23 2009-11-17 Astrazeneca Ab Compounds
US8168668B2 (en) 2005-12-23 2012-05-01 Astrazeneca Ab Compounds
US8501783B2 (en) 2006-03-13 2013-08-06 The Regents Of The University Of California Conformationally restricted urea inhibitors of soluble epoxide hydrolase
US9029550B2 (en) 2006-03-13 2015-05-12 The Regents Of The University Of California Conformationally restricted urea inhibitors of soluble epoxide hydrolase
JP2009530287A (ja) * 2006-03-13 2009-08-27 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 高血圧、炎症および他の疾患の治療のための可溶性エポキシドヒドロラーゼの阻害剤としてのピペリジニル、インドリル、ピリニジル、モルホリニルおよびベンズイミダゾリル尿素誘導体
US8093402B2 (en) 2006-08-11 2012-01-10 Astrazeneca Ab Benzimidazole derivatives
US7906654B2 (en) 2006-08-11 2011-03-15 Astrazeneca Ab Benzimidazole derivatives
WO2008028690A1 (fr) * 2006-09-07 2008-03-13 Bayer Schering Pharma Aktiengesellschaft 1-(hét)aryle-3-[hétaryle-pipéridine-4-yle]-thiourées utilisées en tant que modulateurs du récepteur ep2
EP1903037A1 (fr) * 2006-09-07 2008-03-26 Bayer Schering Pharma Aktiengesellschaft Dérivés de 1-[(hétéro)aryl]-3-[hétéroaryl-pipéridine-4-yl]thiourée en tant que modulateurs de récepteurs EP2
US8653262B2 (en) 2007-05-31 2014-02-18 Boehringer Ingelheim International Gmbh CCR2 receptor antagonists and uses thereof
JP2010530438A (ja) * 2007-06-21 2010-09-09 アイアールエム・リミテッド・ライアビリティ・カンパニー プロテインキナーゼ阻害剤およびその使用法
US8557872B2 (en) 2008-01-28 2013-10-15 Amorepacific Corporation Compounds, isomer thereof, or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist; and pharmaceutical compositions containing the same
US8691855B2 (en) 2008-07-02 2014-04-08 Amorepacific Corporation Compounds, isomer thereof, or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist and pharmaceutical compositions containing the same
US8835440B2 (en) 2008-12-19 2014-09-16 Boehringer Ingelheim International Gmbh Cyclic pyrimidin-4-carboxamides as CCR2 receptor antagonists for treatment of inflammation, asthma and COPD
US9067951B2 (en) 2008-12-19 2015-06-30 Boehringer Ingelheim International Gmbh Process and intermediates for the production of CCR2 antagonists
US11731981B2 (en) 2009-12-17 2023-08-22 Centrexion Therapeutics Corporation CCR2 receptor antagonists and uses thereof
US10196402B2 (en) 2009-12-17 2019-02-05 Centrexion Therapeutics Corporation CCR2 receptor antagonists and uses thereof
US8765949B2 (en) 2009-12-17 2014-07-01 Boehringer Ingelheim International Gmbh CCR2 receptor antagonists and uses thereof
US11046706B2 (en) 2009-12-17 2021-06-29 Centrexion Therapeutics Corporation CCR2 receptor antagonists and uses thereof
US9670222B2 (en) 2009-12-17 2017-06-06 Centrexion Therapeutics Corporation CCR2 receptor antagonists and uses thereof
US8877745B2 (en) 2010-05-12 2014-11-04 Boehringer Ingelheim International Gmbh CCR2 receptor antagonists, method for producing the same, and use thereof as medicaments
US8946218B2 (en) 2010-05-12 2015-02-03 Boehringer Ingelheim International Gmbh CCR2 receptor antagonists, method for producing the same, and use thereof as medicaments
US8841313B2 (en) 2010-05-17 2014-09-23 Boehringer Ingelheim International Gmbh CCR2 antagonists and uses thereof
US9018212B2 (en) 2010-05-25 2015-04-28 Boehringer Ingelheim International Gmbh Pyridazine carboxamides as CCR2 receptor antagonists
US8962656B2 (en) 2010-06-01 2015-02-24 Boehringer Ingelheim International Gmbh CCR2 antagonists
US9108958B2 (en) 2011-07-15 2015-08-18 Boehringer Ingelheim International Gmbh Selective CCR2 antagonists
US10213428B2 (en) 2015-07-02 2019-02-26 Centrexion Therapeutics Corporation (4-((3R,4R)-3-methoxytetrahydro-pyran-4-ylamino)piperidin-1-yl)(5-methyl-6-(((2R,6S)-6-(p-tolyl)tetrahydro-2H-pyran-2-yl)methylamino)pyrimidin-4-yl)methanone citrate
US10568885B2 (en) 2015-07-02 2020-02-25 Centrexion Therapeutics Corporation (4-((3R,4R)-3-methoxytetrahydro-pyran-4-ylamino)piperidin-1-y1)(5-methyl-6-(((2R,6S)-6-(p-tolyl)tetrahydro-2H-pyran-2-citrate
US11147814B2 (en) 2015-07-02 2021-10-19 Centrexion Therapeutics Corporation (4-((3R,4R)-3-methoxytetrahydro-pyran-4-ylamino)piperidin-1-yl)(5-methyl-6-(((2R,6S)-6-(p- tolyl)tetrahydro-2H-pyran-2-yl)methylamino)pyrimidin-4-yl)methanone citrate
DE102022104759A1 (de) 2022-02-28 2023-08-31 SCi Kontor GmbH Co-Kristall-Screening Verfahren, insbesondere zur Herstellung von Co-Kristallen

Also Published As

Publication number Publication date
AU2003270199A1 (en) 2004-04-30

Similar Documents

Publication Publication Date Title
WO2004024710A1 (fr) Composes a base d'uree, actifs en tant qu'antagonistes du recepteur de la vanilloide et utilises pour traiter les douleurs
CA2458632C (fr) Composes d'uree actifs en tant qu'antagonistes du recepteur vanilloide dans le traitement de la douleur
AU2002329397A1 (en) Urea-compounds active as Vanilloid receptor antagonists for the treatment of pain
CA2570197C (fr) Antagonistes de nk<sb>1</sb>
WO2005016922A1 (fr) Derives carbazole-2-carboxamides possedant une activite antagoniste du recepteur vanilloide
WO2005095346A1 (fr) 3-((hetero)arylsulfonyl)-8-{(aminoalkyl)oxy}quinolines servant d'antagonistes au recepteur 5-ht6 pour le traitement de troubles cns
WO2005016915A1 (fr) Derives carboxamides de piperidine/cyclohexane destines a etre utilises comme modulateurs du recepteur vanilloide
US7528151B2 (en) Heterocyclic urea derivatives for the treatment of pain
US7514562B2 (en) Urea derivatives and their use as vanilloid receptor antagonists in the treatment of pain
EP1608640A2 (fr) Derives d'uree ayant une activite d'antagonistes du recepteur vanilloide
ZA200401186B (en) Urea-compounds active as vanilloid receptor antagonists for the treatment of pain.
AU2018271297A1 (en) Piperidine derivatives as nk1 antagonists

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP